Suggested Talking Points: 340B Drug Pricing Program

- The 340B Drug Pricing Program allows safety-net, critical access and children’s specialty hospitals to offer affordable prescription drugs to financially vulnerable and fragile patients.

- It represents less than 3 percent of the $400 billion in drug sales in the U.S.

- Discounted drugs are offered to 340B eligible hospitals by drug manufacturers at no cost to taxpayers.

- The program is small, yet essential to helping qualified providers stretch limited resources and better serve their patients and communities.

- Recent legislative proposals would make the program overly burdensome for participating hospitals and would limit its impact.

- Earlier this year, the Centers for Medicare & Medicaid Services (CMS) drastically reduced the amount Medicare reimburses for drugs purchased through the 340B Drug Pricing Program.

- In Illinois, this policy will result in nearly $73 million in cuts to eligible 340B hospitals and will limit their ability to offer necessary services to vulnerable patients who are the intended beneficiaries of the 340B program.

- Hospitals are committed to maintaining the integrity of the 340B drug pricing program and are subject to random audits by the Health Resources and Services Administration (HRSA). Yet, drug manufacturers are not subject to the same level of accountability or transparency.

- Please cosponsor H.R. 4392, bi-partisan legislation to rescind CMS’ recently imposed Medicare cuts for many hospitals in the 340B program.

- Also, please protect the 340B program from harmful proposals that would limit the participation of eligible hospitals.